Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;46(6):1156-1163.
doi: 10.2337/dc22-2159.

Age of Diagnosis Does Not Alter the Presentation or Progression of Robustly Defined Adult-Onset Type 1 Diabetes

Nicholas J Thomas  1   2 , Anita V Hill  2 , Colin M Dayan  3 , Richard A Oram  1   2 , Timothy J McDonald  1   2 , Beverley M Shields  1 , Angus G Jones  1   2 ; StartRight Study Group
Collaborators, Affiliations

Age of Diagnosis Does Not Alter the Presentation or Progression of Robustly Defined Adult-Onset Type 1 Diabetes

Nicholas J Thomas et al. Diabetes Care. .

Abstract

Objective: To determine whether presentation, progression, and genetic susceptibility of robustly defined adult-onset type 1 diabetes (T1D) are altered by diagnosis age.

Research design and methods: We compared the relationship between diagnosis age and presentation, C-peptide loss (annual change in urine C-peptide-creatinine ratio [UCPCR]), and genetic susceptibility (T1D genetic risk score [GRS]) in adults with confirmed T1D in the prospective StartRight study, 1,798 adults with new-onset diabetes. T1D was defined in two ways: two or more positive islet autoantibodies (of GAD antibody, IA-2 antigen, and ZnT8 autoantibody) irrespective of clinical diagnosis (n = 385) or one positive islet autoantibody and a clinical diagnosis of T1D (n = 180).

Results: In continuous analysis, age of diagnosis was not associated with C-peptide loss for either definition of T1D (P > 0.1), with mean (95% CI) annual C-peptide loss in those diagnosed before and after 35 years of age (median age of T1D defined by two or more positive autoantibodies): 39% (31-46) vs. 44% (38-50) with two or more positive islet autoantibodies and 43% (33-51) vs. 39% (31-46) with clinician diagnosis confirmed by one positive islet autoantibody (P > 0.1). Baseline C-peptide and T1D GRS were unaffected by age of diagnosis or T1D definition (P > 0.1). In T1D defined by two or more autoantibodies, presentation severity was similar in those diagnosed before and after 35 years of age: unintentional weight loss, 80% (95% CI 74-85) vs. 82% (76-87); ketoacidosis, 24% (18-30) vs. 19% (14-25); and presentation glucose, 21 mmol/L (19-22) vs. 21 mmol/L (20-22) (all P ≥ 0.1). Despite similar presentation, older adults were less likely to be diagnosed with T1D, insulin-treated, or admitted to hospital.

Conclusions: When adult-onset T1D is robustly defined, the presentation characteristics, progression, and T1D genetic susceptibility are not altered by age of diagnosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

RA is a co-Investigator on a Randox R&D research grant. The study has received translational industry-academic funding from Randox R&D relating to autoimmune genetic risk scores for prediction and classification of disease. There are no established patents, loyalties or licensing agreements relating to this grant. It is a 3 year grant (Feb 2022-2025). The approximate value is a £2.2m program grant on genetic risk scores across autoimmune disease.

All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.

Figures

Figure 1
Figure 1. Comparison of type 1 diabetes genetic susceptibility (T1DGRS) (a) and recruitment blood C-peptide (b) in participants with type 1 diabetes defined by both study definitions aged below and above age 35 at diabetes diagnosis.
Horizontal lines represent the mean, error bars represent 95% confidence intervals. Comparisons by age group are shown for each definition and across all definitions and age groups.
Figure 2
Figure 2. Progression of change in log UCPCR from mixed effect models with age as an interaction term for a) type 1 diabetes defined by multi-antibody (≥2) positivity and b) a single positive antibody in the context of a clinical diagnosis of type 1 diabetes.
Error bars represent 95% confidence intervals. Comparison type 2 diabetes group shown for reference.
See this image and copyright information in PMC

Comment in

References

    1. Leslie RD, Evans-Molina C, Freund-Brown J, Buzzetti R, Dabelea D, Gillespie KM, Goland R, Jones AG, Kacher M, Phillips LS, Rolandsson O, et al. Adult-Onset Type 1 Diabetes: Current Understanding and Challenges. Diabetes Care. 2021;44:2449–2456. - PMC - PubMed
    1. McKeigue PM, Spiliopoulou A, McGurnaghan S, Colombo M, Blackbourn L, McDonald TJ, Onengut-Gomuscu S, Rich SS, CN AP, McKnight JA, MW JS, et al. Persistent C-peptide secretion in Type 1 diabetes and its relationship to the genetic architecture of diabetes. BMC Med. 2019;17:165. - PMC - PubMed
    1. Barker A, Lauria A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, Scherbaum WA, et al. Age-dependent decline of beta-cell function in type 1 diabetes after diagnosis: a multi-centre longitudinal study. Diabetes Obes Metab. 2014;16:262–267. - PubMed
    1. Davis AK, DuBose SN, Haller MJ, Miller KM, DiMeglio LA, Bethin KE, Goland RS, Greenberg EM, Liljenquist DR, Ahmann AJ, Marcovina SM, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38:476–481. - PubMed
    1. Greenbaum CJ, Beam CA, Boulware D, Gitelman SE, Gottlieb PA, Herold KC, Lachin JM, McGee P, Palmer JP, Pescovitz MD, Krause-Steinrauf H, et al. Type 1 Diabetes TrialNet Study G. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes. 2012;61:2066–2073. - PMC - PubMed

Publication types

LinkOut - more resources